Selinexor in Multiple Myeloma: Clinical Trials and Dosing

Selinexor is the first drug in its class to treat multiple myeloma by blocking a protein called exportin 1, which cancer cells hijack to shuttle tumor-suppressing proteins out of the nucleus where they would otherwise trigger cell death. Approved for use in relapsed or refractory myeloma, it has shown meaningful activity even in patients whose disease has stopped responding to all three major drug classes. But selinexor comes with a distinct side-effect profile that requires proactive management, and the story of how clinicians have learned to use it more effectively over the past several years is as important as its mechanism.

How Selinexor Works

Most cancer drugs for myeloma fall into a handful of categories: proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. Selinexor does something fundamentally different. It blocks exportin 1 (also called XPO1), the primary shuttle that moves large molecules from the cell nucleus out to the cytoplasm. In myeloma cells, exportin 1 is overactive, constantly ferrying tumor suppressor proteins out of the nucleus so they cannot do their job of stopping abnormal growth. Selinexor jams that shuttle. The result is a buildup of tumor suppressors inside the nucleus and a simultaneous drop in the production of cancer-promoting proteins, ultimately pushing myeloma cells into programmed cell death.¹ It also traps the glucocorticoid receptor in the nucleus, which may explain why it pairs well with dexamethasone.²

Because the mechanism is entirely different from the three drug classes most myeloma patients cycle through, selinexor can still work when those agents have stopped working. That matters enormously for patients who are “triple-class refractory,” meaning their disease has progressed on proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Before selinexor, there was essentially no standard treatment for this group, and outcomes were grim.

The STORM Trial and Heavily Pretreated Patients

The trial that earned selinexor its first regulatory attention was STORM, a phase 2b study that enrolled patients with penta-refractory myeloma, meaning their cancer had become resistant to at least five prior drugs spanning all major classes. These are patients who have exhausted nearly every standard option. Selinexor was given with low-dose dexamethasone, and the combination achieved an overall response rate of about 26% with a median overall survival of roughly 8.6 months.³ In a population with so few remaining options, getting one in four patients to respond was considered a genuine advance, though the side-effect burden in STORM was considerable, as we will see.

The BOSTON Trial and the Shift to Triplet Therapy

If STORM proved selinexor could work, the phase 3 BOSTON trial reshaped how clinicians actually use it. BOSTON enrolled patients who had received one to three prior lines of therapy and compared a triplet of once-weekly selinexor plus once-weekly bortezomib and dexamethasone (abbreviated XVd or SVd) against the standard doublet of twice-weekly bortezomib and dexamethasone (Vd). The triplet won on multiple fronts: longer progression-free survival, higher response rates, deeper responses, and a trend toward improved overall survival.⁴ Perhaps most surprising, patients on the selinexor-containing arm had lower rates of peripheral neuropathy, which is one of the most troublesome side effects of bortezomib. The once-weekly dosing of bortezomib in the triplet regimen, compared to the conventional twice-weekly schedule, likely explains much of that benefit.⁵

BOSTON established SVd as a viable option earlier in the treatment journey, not just a last resort for penta-refractory disease. It moved the conversation from “can we rescue anything?” to “can we get better disease control with acceptable toxicity?”

Combinations Beyond Bortezomib

Selinexor’s novel mechanism makes it a natural candidate for pairing with other myeloma drugs, and several combinations have been studied. One of the more promising is selinexor plus carfilzomib (a more potent proteasome inhibitor than bortezomib) and dexamethasone. A phase 1 study of this triplet in relapsed or refractory patients, including many who were already refractory to carfilzomib, showed a partial response or better in about 48% of patients, with an overall survival exceeding 22 months.⁶ A follow-up study using an all-once-weekly schedule in carfilzomib non-refractory patients reported even stronger results: a 78% overall response rate and a median progression-free survival of 15 months, though roughly half the patients had high-risk genetic features.⁷

Combinations with immunomodulatory drugs, including lenalidomide and pomalidomide alongside dexamethasone, have also been explored, with early data showing activity in triple-class refractory and high-risk populations. The flexibility of selinexor to slot into different backbone regimens is one of its more useful features in practice, especially for patients who have limited options left.

The Side-Effect Profile and Why It Demands Attention

Selinexor’s side effects are real and can be severe if not managed proactively. The most common issues fall into two buckets: gastrointestinal symptoms and low blood counts.

Nausea, loss of appetite, vomiting, and fatigue were reported in the majority of patients across trials. In the early STORM study, where higher and more frequent dosing was used, these symptoms were particularly burdensome. A phase 1b exploration found that prophylactic use of olanzapine at a low dose helped reduce nausea and vomiting compared to not using it, though the differences did not reach statistical significance in a small sample.⁸ In practice, most myeloma centers now use multi-agent anti-nausea regimens, often starting olanzapine and ondansetron before the first dose of selinexor, rather than waiting for symptoms to appear.

Thrombocytopenia, or low platelet counts, is the other hallmark toxicity. Across 437 patients enrolled in clinical trials, about two-thirds developed some degree of thrombocytopenia, and roughly a third had grade 4 events (platelet counts dropping very low). Platelet counts typically started falling within the first week of treatment and hit their lowest point between four and six weeks in without intervention. The good news: for patients who continued therapy, platelets stabilized after that initial drop and did not keep declining further. Severe bleeding with concurrent low platelets was uncommon, occurring in fewer than 3% of cases.⁹

Researchers have worked out the mechanism behind this platelet drop: selinexor blocks the signaling pathway that stem cells use to mature into platelet-producing cells. The inhibition is reversible, and platelet counts can recover during drug holidays or with the use of thrombopoietin receptor agonists, drugs that stimulate platelet production through a parallel pathway.¹⁰ Platelet transfusions were used in about 27% of patients across the integrated safety analysis, with most episodes resolving within about eight days.¹¹

Hyponatremia, or low sodium levels, is another side effect to watch. In one early study, about a quarter of patients developed grade 3 hyponatremia, though most cases were asymptomatic and easily corrected with sodium supplementation.¹²

Lower Doses, Better Tolerability

One of the clearest lessons from the past several years is that less selinexor often delivers just as much benefit with considerably fewer side effects. The STORM trial used 80 mg twice weekly, a schedule that was effective but hard on patients. The BOSTON trial dialed back to 100 mg once weekly in combination with bortezomib, and the rates of grade 3 or higher fatigue and nausea dropped substantially. Across BOSTON, about 65% of patients on the selinexor arm needed dose reductions, with a median final dose of roughly 71 mg per week.¹³

Counterintuitively, patients who needed dose reductions in BOSTON actually had better outcomes than those who did not: longer progression-free survival (about 16.6 versus 9.2 months) and higher response rates (82% versus 67%). There are caveats to that finding, because patients who are already responding well may be more motivated to stay on treatment with a dose reduction, and those with aggressive disease may stop treatment before a reduction ever happens. Still, the data strongly suggest that lower, once-weekly dosing maintains anti-myeloma activity while making the drug much more livable for patients.¹⁴

Real-world experience echoes this. In one observational study of 44 patients treated outside clinical trials, 56% required dose reductions, but the reductions were not associated with worse progression-free survival.¹⁵ The clinical community has clearly moved toward starting lower and adjusting rather than pushing aggressive dosing schedules.

High-Risk Cytogenetics and Extramedullary Disease

Certain genetic changes in myeloma cells are associated with faster relapse and shorter survival, and patients with these high-risk features are among the hardest to treat. In a subgroup analysis of the BOSTON trial, the SVd triplet outperformed standard Vd in both high-risk and standard-risk groups. Among high-risk patients, median progression-free survival was about 12.9 months with SVd compared to 8.6 months with Vd, and the proportion of patients achieving deep responses was roughly double in the selinexor arm.¹⁶ These are encouraging numbers for a group that often does not respond as well to standard regimens.

Extramedullary disease, where myeloma grows outside the bone marrow in soft tissues or organs, is another scenario where selinexor has shown early promise. A phase 2 trial tested selinexor combined with bortezomib, lenalidomide, and dexamethasone (a four-drug regimen called XVRd) in newly diagnosed myeloma patients with extramedullary involvement. Among 10 patients with measurable extramedullary lesions, four saw them disappear completely after induction, and the remaining six had measurable shrinkage.¹⁷ The safety profile of the four-drug combination was manageable, with no treatment-related deaths and grade 3 or 4 events primarily limited to low blood counts.¹⁸ These are small numbers, and extramedullary disease remains a difficult challenge, but the results provide a rationale for continued investigation.

What Real-World Data Show

Clinical trials select patients carefully, so outcomes outside trials are an important reality check. A real-world study of patients treated with selinexor-based triplet regimens reported a median overall survival of about 14.7 months and a derived progression-free survival of roughly 4.7 months. Patients who had recently been treated with an anti-CD38 antibody before starting selinexor did numerically better, with a median overall survival of about 20.9 months.¹⁹ That observation aligns with the idea that selinexor’s novel mechanism can pick up where other drug classes leave off.

Another real-world analysis found a response rate of about 30% across all treated patients, with the SVd triplet outperforming selinexor-dexamethasone alone (35% versus 24%). Two factors stood out as predictors of poorer outcomes: low serum albumin and elevated LDH, both of which are markers of more aggressive disease biology. Among patients who progressed on selinexor and went on to receive further therapy, 40% responded to the next line of treatment, suggesting that selinexor does not necessarily burn bridges for future options.²⁰

Predicting Who Will Respond

One limitation of selinexor, shared with many cancer drugs, is that it does not work for everyone, and identifying who will benefit ahead of time could spare patients unnecessary side effects. Researchers have identified a three-gene signature involving the genes WNT10A, DUSP1, and ETV7 that appears to predict response to selinexor-based therapy. The signature was developed using data from the BOSTON trial, validated in the STORM cohort and in an external group of patients treated outside clinical trials, and it correlated with both the depth and duration of response. The genes involved hint at a mechanism: tumors with upregulated interferon-mediated death signaling may be primed to respond when selinexor traps tumor suppressors in the nucleus.²¹

Separately, a gene called ABCC4 has been flagged as both a potential resistance biomarker and a prognostic marker. Higher expression of ABCC4 correlated with reduced selinexor sensitivity in myeloma cell lines and worse survival outcomes in patients. Interestingly, the researchers found that selinexor sensitivity was not limited to specific cytogenetic subtypes, meaning the drug’s potential reach is broad even if not everyone responds equally.²² Neither of these biomarker tools is in routine clinical use yet, but they represent active areas of research that could change how oncologists select patients for selinexor-containing regimens in the future.

Cost and Access

Selinexor is expensive, and the cost-effectiveness picture is not straightforward. One economic analysis based on the BOSTON trial estimated that adding selinexor to bortezomib and dexamethasone cost roughly $170,000 more than the doublet alone over a patient’s lifetime, for an incremental gain of about 0.35 quality-adjusted life years. That works out to an incremental cost-effectiveness ratio far above typical willingness-to-pay thresholds used in health-economic assessments.²³ In plainer terms, the analysis concluded that adding selinexor in this setting is unlikely to be considered cost-effective by conventional standards.

That does not necessarily mean it is the wrong choice for individual patients, especially those with no good alternatives. Cost-effectiveness models describe averages across populations; for a specific patient whose disease has stopped responding to everything else, even modest gains in survival or symptom control can be valuable. But the high cost does affect access, and patients may encounter insurance hurdles, particularly for the selinexor-dexamethasone doublet used in penta-refractory disease where alternatives are essentially absent.

Next-Generation Exportin 1 Inhibitors

Part of selinexor’s side-effect burden, particularly the nausea and appetite loss, appears linked to the drug’s ability to cross into the brain. A second-generation compound called eltanexor (KPT-8602) was designed to have similar anti-cancer potency but substantially less brain penetration. In preclinical studies, eltanexor showed markedly better tolerability with minimal appetite suppression and weight loss compared to selinexor.²⁴ Early-phase clinical trials have been underway, and if the improved tolerability holds up in larger studies, eltanexor could eventually offer the same mechanism of action in a more patient-friendly package. For now, selinexor remains the only approved drug in this class, but the principle that you can target exportin 1 more selectively with fewer central nervous system effects is an active area of drug development that patients and clinicians are watching closely.